FDG-PET/CT after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: Results of a Nordic/US intergroup study

Karen Juul Mylam; Lale Kostakoglu; Martin Hutchings; Morton Coleman; Dominic Lamonica; Myron S Czuczman; Louis F Diehl; Anne L Nielsen; Paw Jensen; Annika Loft; Helle W Hendel; Victor Iyer; Sirpa Leppä; Sirkku Jyrkkiö; Harald Holte; Mikael Eriksson; Dorte Gillstrøm; Per B Hansen; Marko Seppänen; Karin Hjorthaug; Peter de Nully Brown; Lars M Pedersen

doi:10.3109/10428194.2014.975800

FDG-PET/CT after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: Results of a Nordic/US intergroup study

Karen Juul Mylam, Lale Kostakoglu, Martin Hutchings, Morton Coleman, Dominic Lamonica, Myron S Czuczman, Louis F Diehl, Anne L Nielsen, Paw Jensen, Annika Loft, Helle W Hendel, Victor Iyer, Sirpa Leppä, Sirkku Jyrkkiö, Harald Holte, Mikael Eriksson, Dorte Gillstrøm, Per B Hansen, Marko Seppänen, Karin HjorthaugPeter de Nully Brown, Lars M Pedersen

Afdeling for Klinisk Fysiologi og Nuklearmedicin

25 Citationer (Scopus)

Abstract

ABSTRACT We evaluated the predictive value of I-PET after one course of chemoimmunotherapy in patients with newly diagnosed DLBCL. 112 DLBCL patients were enrolled. All patients had PET/CT scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to International harmonization project criteria (IHP) and to Deauville 5 point scale (D 5PS) with scores 1-3 considered negative (D 5PS>3) and D 5PS with scores 1-4 considered negative (D5PS=5). Ratios of tumorSUVmax to liverSUVmax were also analyzed. We found no difference in progression-free survivals (PFS) between PET-negative and PET-positive patients according to IHP and D 5PS>3. The 2-year PFS using D 5PS=5 was 50.9% in the PET-positive group and 84.8% in the PET-negative group (p=0.002). A tumor/liver SUVmax cut-off of 3.1 to distinguish a D 5PS scores of 4 and 5 provided the best prognostic value. PET after one course of chemotherapy was not able to safely discriminate PET positive and PET negative patients in different prognostic groups.

Originalsprog	Engelsk
Tidsskrift	Leukemia and Lymphoma
Vol/bind	56
Udgave nummer	7
Sider (fra-til)	2005-12
ISSN	1042-8194
DOI	https://doi.org/10.3109/10428194.2014.975800
Status	Udgivet - 2015

Adgang til dokumentet

10.3109/10428194.2014.975800

Citationsformater

Mylam, K. J., Kostakoglu, L., Hutchings, M., Coleman, M., Lamonica, D., Czuczman, M. S., Diehl, L. F., Nielsen, A. L., Jensen, P., Loft, A., Hendel, H. W., Iyer, V., Leppä, S., Jyrkkiö, S., Holte, H., Eriksson, M., Gillstrøm, D., Hansen, P. B., Seppänen, M., ... Pedersen, L. M. (2015). FDG-PET/CT after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: Results of a Nordic/US intergroup study. Leukemia and Lymphoma, 56(7), 2005-12. https://doi.org/10.3109/10428194.2014.975800

Mylam, KJ, Kostakoglu, L, Hutchings, M, Coleman, M, Lamonica, D, Czuczman, MS, Diehl, LF, Nielsen, AL, Jensen, P, Loft, A , Hendel, HW, Iyer, V, Leppä, S, Jyrkkiö, S, Holte, H, Eriksson, M, Gillstrøm, D, Hansen, PB, Seppänen, M, Hjorthaug, K, de Nully Brown, P & Pedersen, LM 2015, 'FDG-PET/CT after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: Results of a Nordic/US intergroup study', Leukemia and Lymphoma, bind 56, nr. 7, s. 2005-12. https://doi.org/10.3109/10428194.2014.975800

@article{d5078cdd937e44c4bc8c70bd2ad16913,

title = "FDG-PET/CT after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: Results of a Nordic/US intergroup study",

abstract = "ABSTRACT We evaluated the predictive value of I-PET after one course of chemoimmunotherapy in patients with newly diagnosed DLBCL. 112 DLBCL patients were enrolled. All patients had PET/CT scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to International harmonization project criteria (IHP) and to Deauville 5 point scale (D 5PS) with scores 1-3 considered negative (D 5PS>3) and D 5PS with scores 1-4 considered negative (D5PS=5). Ratios of tumorSUVmax to liverSUVmax were also analyzed. We found no difference in progression-free survivals (PFS) between PET-negative and PET-positive patients according to IHP and D 5PS>3. The 2-year PFS using D 5PS=5 was 50.9% in the PET-positive group and 84.8% in the PET-negative group (p=0.002). A tumor/liver SUVmax cut-off of 3.1 to distinguish a D 5PS scores of 4 and 5 provided the best prognostic value. PET after one course of chemotherapy was not able to safely discriminate PET positive and PET negative patients in different prognostic groups.",

author = "Mylam, {Karen Juul} and Lale Kostakoglu and Martin Hutchings and Morton Coleman and Dominic Lamonica and Czuczman, {Myron S} and Diehl, {Louis F} and Nielsen, {Anne L} and Paw Jensen and Annika Loft and Hendel, {Helle W} and Victor Iyer and Sirpa Lepp{\"a} and Sirkku Jyrkki{\"o} and Harald Holte and Mikael Eriksson and Dorte Gillstr{\o}m and Hansen, {Per B} and Marko Sepp{\"a}nen and Karin Hjorthaug and {de Nully Brown}, Peter and Pedersen, {Lars M}",

year = "2015",

doi = "10.3109/10428194.2014.975800",

language = "English",

volume = "56",

pages = "2005--12",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "7",

}

TY - JOUR

T1 - FDG-PET/CT after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma

T2 - Results of a Nordic/US intergroup study

AU - Mylam, Karen Juul

AU - Kostakoglu, Lale

AU - Hutchings, Martin

AU - Coleman, Morton

AU - Lamonica, Dominic

AU - Czuczman, Myron S

AU - Diehl, Louis F

AU - Nielsen, Anne L

AU - Jensen, Paw

AU - Loft, Annika

AU - Hendel, Helle W

AU - Iyer, Victor

AU - Leppä, Sirpa

AU - Jyrkkiö, Sirkku

AU - Holte, Harald

AU - Eriksson, Mikael

AU - Gillstrøm, Dorte

AU - Hansen, Per B

AU - Seppänen, Marko

AU - Hjorthaug, Karin

AU - de Nully Brown, Peter

AU - Pedersen, Lars M

PY - 2015

Y1 - 2015

N2 - ABSTRACT We evaluated the predictive value of I-PET after one course of chemoimmunotherapy in patients with newly diagnosed DLBCL. 112 DLBCL patients were enrolled. All patients had PET/CT scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to International harmonization project criteria (IHP) and to Deauville 5 point scale (D 5PS) with scores 1-3 considered negative (D 5PS>3) and D 5PS with scores 1-4 considered negative (D5PS=5). Ratios of tumorSUVmax to liverSUVmax were also analyzed. We found no difference in progression-free survivals (PFS) between PET-negative and PET-positive patients according to IHP and D 5PS>3. The 2-year PFS using D 5PS=5 was 50.9% in the PET-positive group and 84.8% in the PET-negative group (p=0.002). A tumor/liver SUVmax cut-off of 3.1 to distinguish a D 5PS scores of 4 and 5 provided the best prognostic value. PET after one course of chemotherapy was not able to safely discriminate PET positive and PET negative patients in different prognostic groups.

AB - ABSTRACT We evaluated the predictive value of I-PET after one course of chemoimmunotherapy in patients with newly diagnosed DLBCL. 112 DLBCL patients were enrolled. All patients had PET/CT scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to International harmonization project criteria (IHP) and to Deauville 5 point scale (D 5PS) with scores 1-3 considered negative (D 5PS>3) and D 5PS with scores 1-4 considered negative (D5PS=5). Ratios of tumorSUVmax to liverSUVmax were also analyzed. We found no difference in progression-free survivals (PFS) between PET-negative and PET-positive patients according to IHP and D 5PS>3. The 2-year PFS using D 5PS=5 was 50.9% in the PET-positive group and 84.8% in the PET-negative group (p=0.002). A tumor/liver SUVmax cut-off of 3.1 to distinguish a D 5PS scores of 4 and 5 provided the best prognostic value. PET after one course of chemotherapy was not able to safely discriminate PET positive and PET negative patients in different prognostic groups.

U2 - 10.3109/10428194.2014.975800

DO - 10.3109/10428194.2014.975800

M3 - Journal article

C2 - 25330442

SN - 1042-8194

VL - 56

SP - 2005

EP - 2012

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 7

ER -

FDG-PET/CT after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: Results of a Nordic/US intergroup study

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater